Convergence Investment Partners, LLC Abb Vie Inc. Transaction History

Convergence Investment Partners, LLC

$365 Million
Q3 2024

A detailed history of Convergence Investment Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Convergence Investment Partners, LLC holds 29,847 shares of ABBV stock, worth $5.37 Million. This represents 1.61% of its overall portfolio holdings.

Number of Shares

29,847

Previous 29,313 1.82%

Holding current value

$5.37 Million

Previous $5.03 Million 17.25%

% of portfolio

1.61%

Previous 1.48%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	BUY	$163.84 - $199.33 $87,490 - $106,442	534 Added 1.82%	29,847 $5.89 Million
Q2 2024 Aug 01, 2024	BUY	$154.79 - $180.76 $803,824 - $938,686	5,193 Added 21.53%	29,313 $5.03 Million
Q1 2024 May 03, 2024	BUY	$159.82 - $182.1 $176,601 - $201,220	1,105 Added 4.8%	24,120 $4.39 Million
Q4 2023 Feb 05, 2024	SELL	$137.6 - $154.97 $89,990 - $101,350	-654 Reduced 2.76%	23,015 $3.57 Million
Q3 2023 Nov 02, 2023	SELL	$133.59 - $154.65 $11,622 - $13,454	-87 Reduced 0.37%	23,669 $3.53 Million
Q2 2023 Jul 26, 2023	SELL	$132.51 - $164.9 $40,018 - $49,799	-302 Reduced 1.26%	23,756 $3.2 Million
Q1 2023 May 09, 2023	SELL	$144.61 - $166.54 $48,733 - $56,123	-337 Reduced 1.38%	24,058 $3.83 Million
Q4 2022 Feb 03, 2023	BUY	$138.31 - $165.87 $40,109 - $48,102	290 Added 1.2%	24,395 $3.94 Million
Q3 2022 Nov 08, 2022	SELL	$134.21 - $153.93 $30,331 - $34,788	-226 Reduced 0.93%	24,105 $3.24 Million
Q2 2022 Aug 05, 2022	BUY	$137.62 - $174.96 $74,727 - $95,003	543 Added 2.28%	24,331 $3.73 Million
Q1 2022 Apr 26, 2022	BUY	$131.98 - $163.75 $70,609 - $87,606	535 Added 2.3%	23,788 $3.86 Million
Q4 2021 Jan 25, 2022	BUY	$107.43 - $135.93 $303,167 - $383,594	2,822 Added 13.81%	23,253 $3.15 Million
Q3 2021 Oct 25, 2021	SELL	$106.4 - $120.78 $885,248 - $1 Million	-8,320 Reduced 28.94%	20,431 $2.2 Million
Q2 2021 Jul 19, 2021	BUY	$105.21 - $117.21 $267,443 - $297,947	2,542 Added 9.7%	28,751 $3.24 Million
Q1 2021 Apr 30, 2021	SELL	$102.3 - $112.62 $136,672 - $150,460	-1,336 Reduced 4.85%	26,209 $2.84 Million
Q4 2020 Feb 05, 2021	SELL	$80.49 - $108.67 $1.46 Million - $1.97 Million	-18,124 Reduced 39.69%	27,545 $2.95 Million
Q3 2020 Oct 28, 2020	SELL	$85.91 - $100.83 $824,907 - $968,169	-9,602 Reduced 17.37%	45,669 $4 Million
Q2 2020 Jul 30, 2020	BUY	$73.37 - $98.18 $182,471 - $244,173	2,487 Added 4.71%	55,271 $5.43 Million
Q1 2020 Apr 23, 2020	SELL	$64.5 - $97.79 $182,986 - $277,430	-2,837 Reduced 5.1%	52,784 $4.02 Million
Q4 2019 Jan 22, 2020	SELL	$72.13 - $90.25 $345,791 - $432,658	-4,794 Reduced 7.94%	55,621 $4.93 Million
Q3 2019 Oct 22, 2019	SELL	$62.98 - $75.72 $196,875 - $236,700	-3,126 Reduced 4.92%	60,415 $4.58 Million
Q2 2019 Jul 23, 2019	SELL	$65.7 - $83.98 $336,186 - $429,725	-5,117 Reduced 7.45%	63,541 $4.62 Million
Q1 2019 May 01, 2019	SELL	$77.14 - $90.79 $236,048 - $277,817	-3,060 Reduced 4.27%	68,658 $5.53 Million
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $353,594 - $436,077	4,542 Added 6.76%	71,718 $6.61 Million
Q3 2018 Nov 13, 2018	SELL	$88.91 - $98.84 $3.23 Million - $3.59 Million	-36,301 Reduced 35.08%	67,176 $6.35 Million
Q2 2018 Aug 07, 2018	BUY	$89.78 - $106.23 $224,180 - $265,256	2,497 Added 2.47%	103,477 $9.59 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $1.16 Million - $1.55 Million	-12,563 Reduced 11.06%	100,980 $9.56 Million
Q4 2017 Jan 16, 2018	BUY	$89.56 - $98.21 $609,903 - $668,810	6,810 Added 6.38%	113,543 $11 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $7.46 Million - $9.52 Million	106,733	106,733 $9.48 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Convergence Investment Partners, LLC with notifications on news.

Account

Convergence Investment Partners, LLC Abb Vie Inc. Transaction History